• Intestinal TM6SF2, MASH and the Gut–Liver Axis

  2026-08-31

  The reference study shows that intestinal epithelial TM6SF2 protects against metabolic dysfunction-associated steatohepatitis by maintaining barrier integrity and restraining microbiota- and lipid-mediated signals to the liver. Its genetic, germ-free transplantation, co-housing and pharmacological experiments identify lysophosphatidic acid as a gut–liver mediator and provide a framework for testing inflammation and monocyte-trafficking mechanisms in follow-up studies.

• Chlorpromazine in Hepatic Nanoparticle Assays

  2026-08-31

  Chlorpromazine supports two complementary research paths: controlled dopamine receptor signaling studies and hypothesis-driven tests of hepatic nanoparticle uptake. This guide translates findings on PEGylated iron oxide nanoparticles into practical workflows while defining where chlorpromazine hydrochloride is a useful perturbation and where its nonspecific pharmacology limits interpretation.

• Kaempferol, NF-κB/PTGS2, and Melanocyte Ferroptosis

  2026-08-30

  A 2026 study identifies NF-κB/PTGS2 signaling as a mechanistic link between inflammatory activation and ferroptotic melanocyte injury in vitiligo. Using primary melanocytes, transcriptomics, pharmacological pathway testing, and lesional skin analysis, the authors show that kaempferol suppresses this axis and reduces multiple ferroptosis-associated readouts.

• AM251 Workflow for CB1 Receptor Research

  2026-08-29

  AM251 provides a nanomolar pharmacological control for testing whether CB1 signaling contributes to pain, neuronal, metabolic, or cell-fate phenotypes. This workflow connects antagonist design, solvent handling, behavioral readouts, and orthogonal molecular assays for more interpretable cannabinoid receptor research.

• CHK1 Inhibition in ER/PR-Defined Breast Cancer

  2026-08-28

  The reference study shows that CHK1 inhibition has different therapeutic consequences in breast cancer depending on oestrogen-receptor and progesterone-receptor status. It links these differences to distinct cell-cycle and apoptosis pathways, providing a molecular framework for selecting CHK1-directed strategies rather than treating breast cancer as a uniform disease.

• Danazol Research Workflows for Endocrine Models

  2026-08-28

  Danazol enables controlled interrogation of androgen receptor signaling, steroidogenesis, and hypothalamic–pituitary–gonadal axis phenotypes. This guide connects cell-based mechanism assays with a rat precocious-puberty model and provides practical formulation, workflow, and troubleshooting strategies.

• Clarithromycin in CYP3A Assay Design

  2026-08-28

  Clarithromycin is a potent CYP3A inhibitor with important applications in drug-drug interaction research. This guide explains how to use it as a mechanistic perturbation, interpret results alongside dabigatran, and build more defensible pharmacokinetic studies.

• Cinoxacin: A Translational Lens on Gram-Negative DNA

  2026-08-27

  Cinoxacin offers translational researchers a defined model for connecting bacterial DNA synthesis inhibition, urinary exposure, susceptibility testing, and resistance strategy. This article moves beyond product description to explain how its spectrum, pharmacokinetics, and limitations can shape rigorous urinary tract infection research.

• Doxorubicin in 3D Cancer Microtissue Assays

  2026-08-26

  Use Doxorubicin as a mechanistically anchored stress test for collagen-based 3D cancer models, not merely as a viability-control compound. This workflow connects Adriamycin exposure with hypoxia, stemness, apoptosis, drug penetration, and treatment resistance measurements.

• Torin2: Decoding mTOR-Linked Cell Death

  2026-08-26

  Torin2 is a potent mTOR inhibitor for separating pathway suppression from downstream cell-death mechanisms. This article connects Torin2 assay design with new evidence that Pol II degradation can activate death independently of transcriptional loss, improving mechanistic interpretation in cancer research.

• NSC-23766 Workflow for Rac1 Mechanism Studies

  2026-08-26

  NSC-23766 is a Rac GTPase inhibitor for separating Rac1-dependent actin remodeling, barrier disruption, apoptosis, and cell-cycle phenotypes. This workflow translates a CD47–Vav–Rac phagocytosis mechanism into practical dose-response, live-imaging, biochemical, and rescue experiments.

• PLGA Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-08-25

  A 2026 Poultry Science study developed PEI-LSP-RA-PLGA, a PLGA-based multilayer nano-adjuvant designed to combine sustained release, intestinal targeting, and immune stimulation for an inactivated H9N2 avian influenza vaccine. In chicks, the formulation increased serum IgG and intestinal IgA while engaging chemokine-guided intestinal trafficking and Toll-like, NOD-like, and IgA-associated immune pathways.

• SMYD2 Inhibition in Cisplatin-Induced Renal Fibrosis

  2026-08-24

  The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced renal fibrosis and inflammation. By combining AZ505 and LLY507 treatment with animal and tubular epithelial cell experiments, the authors link SMYD2 inhibition to reduced epithelial–mesenchymal transition, extracellular matrix accumulation, inflammatory cytokines, and Smad3/STAT3 signaling.

• Jasplakinolide: Actin Workflows and Troubleshooting

  2026-08-24

  Jasplakinolide is a membrane-permeable actin polymerization inducer for controlled studies of filament assembly, stabilization, cell morphology, and cytotoxicity. This workflow-oriented guide covers dosing, imaging, controls, comparative use cases, and troubleshooting across mammalian and fungal models.

• TRIM21, ERK1/2, and Drug Resistance in Pituitary Adenomas

  2026-08-23

  The reference study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and resistance to dopamine agonists. By combining CRISPR screening with proteomic, ubiquitination, interaction, and in vivo studies, it proposes TRIM21 suppression as a treatment concept while highlighting the need to account for ERK1/2 feedback behavior.

449 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page